Anti-(human Vascular Endothelial Growth Factor Receptor 2) (human Monoclonal Ttac-0001 Heavy Chain) Uses, Dosage, Side Effects and more
Anti-(human Vascular Endothelial Growth Factor Receptor 2) (human Monoclonal Ttac-0001 Heavy Chain) is under investigation in clinical trial NCT03033524 (Trial to Evaluate the Safety of Ttac-0001(tanibirumab) in Recurrent Glioblastoma).
| Trade Name | Anti-(human Vascular Endothelial Growth Factor Receptor 2) (human Monoclonal Ttac-0001 Heavy Chain) |
| Generic | Olinvacimab |
| Olinvacimab Other Names | Fully human monoclonal antibody targets vascular endothelial growth factor receptor 2, Immunoglobulin g1, anti-(human vascular endothelial growth factor receptor 2) (human monoclonal ttac-0001 heavy chain), disulfide with human monoclonal ttac-0001 light chain, dimer, Olinvacimab, Tanibirumab |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
